Skip to main content
Equibles
PBH logo

PBH · Prestige Consumer Healthcare Inc.

Track PBH — free

Use PBH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$52.26 -0.30 (-0.57%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.49B
Shares
47.37M

PBH metrics

83 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$52.26
Market cap
$2.49B

Price action

19 metrics
Price change (1W)
-0.4%
Price change (30D)
-4.0%
Price change (3M)
+10.8%
Price change (6M)
-22.2%
Price change (YTD)
-15.3%
Price change (1Y)
-21.7%
Trailing year
Price change (5Y)
-9.1%
52-week high
$70.21
52-week low
$45.44
Change from 52-week high
-25.6%
Change from 52-week low
+15.0%
Annualized volatility
31.1%
Beta
0.0
RSI (14D)
53.0
Price vs SMA 50
+3.0%
Price vs SMA 200
-8.0%
Avg volume (3M)
579,129
Relative volume
0.6
Average dollar volume
$28.82M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
47.37M

Valuation

12 metrics
P / E (TTM)
14.6
Trailing earnings · reciprocal yield 6.8%
PEG ratio
—
EV / revenue
4.0×
reciprocal yield 25.0%
EV / EBITDA
13.7×
reciprocal yield 7.3%
EV / EBIT
15.2×
reciprocal yield 6.6%
P / sales
2.3×
reciprocal yield 44.4%
P / book
1.3
reciprocal yield 77.0%
FCF yield
9.5%
TTM · current market cap
Buyback yield
4.9%
P / FCF
10.6
reciprocal yield 9.5%
P / operating cash flow
10.0
reciprocal yield 10.0%
Earnings yield
6.9%

Historical valuation

8 metrics
P / E historical average (3Y)
16.8×
reciprocal yield 6.0%
P / E historical average (5Y)
16.1×
reciprocal yield 6.2%
EV / revenue historical average (3Y)
3.8×
reciprocal yield 26.0%
EV / revenue historical average (5Y)
3.9×
reciprocal yield 25.5%
EV / EBIT historical average (3Y)
13.1×
reciprocal yield 7.6%
EV / EBIT historical average (5Y)
13.2×
reciprocal yield 7.6%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
4.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
53.5%
Operating margin
26.3%
Trailing 12 months
Net margin
15.6%
Gross profit (TTM)
$591.43M
Operating profit (TTM)
$290.17M
Net income (TTM)
$172.01M
Trailing 12 months
Diluted EPS (TTM)
$3.57
FCF margin
21.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+6.5%
Year over year
Net income growth YoY
-38.5%
Revenue (TTM)
$1.10B
Trailing 12 months
EPS growth YoY
-35.8%
Shares change YoY
-4.5%
Year over year · fewer shares
Revenue CAGR (3Y)
-1.2%
Revenue CAGR (5Y)
+2.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
+3.8%
FCF CAGR (3Y)
+3.6%
FCF CAGR (5Y)
+2.9%

Quality

14 metrics
Return on equity
9.0%
Return on assets
3.8%
Debt / equity
1.1
Current ratio
3.2
EBITDA (TTM)
$322.53M
Free cash flow (TTM)
$235.36M
Quick ratio
2.0
Interest coverage
—
Net debt / EBITDA
6.0
Return on invested capital
—
Trailing 12 months
Net cash
−$1.93B
Latest balance sheet
Cash & equivalents
$89.13M
Total assets
$4.57B
Total debt
$2.02B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$249.40M
Capital expenditures (TTM)
$14.04M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$11.15M
R&D / revenue
—
Stock compensation / revenue
1.0%

Ownership (13F)

3 metrics
13F filers
318
13F filer change QoQ
-36
Institutional ownership
113.0%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 6.2 days to cover
Days to cover
6.2d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1295947 CUSIP 74112D101 13F (30d) 216 filings 216 filers Visit website Investor relations